Susan J. Schniepp, distinguished fellow for Regulatory Compliance Associates, and Shiri Hechter, senior lab operations manager for Nelson Laboratories, provide a simple approach to method validation and validating analytical methods.
Q. How can an analytical method be validated?
A. When using an analytical method published in a pharmacopeia, the method is considered validated and it just needs to be verified under actual conditions of use. However, when using analytical methods for routine testing that are not published in the pharmacopeias, it is expected that the method would be validated.
United States Pharmacopeia
The United States Pharmacopeia defines validation of an analytical procedure as
“the process by which it is established, by laboratory studies, that the performance characteristics of the procedure meet the requirements for the intended analytical applications”.
The European Directorate for the Quality of Medicines and HealthCare (EDQM), which publishes the European Pharmacopoeia (Ph. Eur.), takes a similar approach stating,
“This chapter defines the different analytical situations (categories) which might occur in an OMCL [official medicines control laboratories] and the corresponding validation characteristics which should be considered. Refer to the current version of the ICH [International Council for Harmonisation] guideline on ‘Validation of Analytical Procedures: Text and Methodology (Q2)’ ”.
Analytical Method Validation
The following examples of industry guidelines provide rationale and approach when validating analytical methods:
- The United States Pharmacopeia–National Formulary (USP–NF) general chapter <1225> Validation of Compendial Procedures
- PA/PH/OMCL (13) 82 R5, Validation/Verification of Analytical Procedures revised in July 2020
- FDA’s Analytical Procedures and Methods Validation for Drugs and Biologics, Guidance for Industry, July 2015
- ICH guideline Q2(R2) on validation of analytical procedures (currently under public consultation) published March 31, 2022.
These documents are inter-connected because they reference each other and the approach they define is based on defining “Typical analytical performance characteristics that should be considered in the validation of the types of procedures …”.
In USP General Chapter <1225>, some typical performance characteristics referred to are accuracy, precision, specificity, detection limit, quantitation limit, linearity, range, and robustness. These characteristics should all be considered when determining the validation approach for any analytical procedure.
USP <1225> aims at compendial procedures that include routine tests on raw materials and finished products. The FDA guidance covers new drug applications, abbreviated new drug applications, biologics license applications, and supplements to these applications. Definitions, data elements, and acceptance levels are well documented in these publications. Depending on the objectives of the analytical validation method, data elements could vary.
For example, USP <1225> defines four categories for consideration. The chapter indicates that Category I–Assay, does not need to have detection limit, whereas Category II–Limit Tests, requires detection limit. The full data elements required for method qualification and validation are detailed in Table 2 in USP <1225>.
Similar instructions can be found in ICH guideline Q2(R2) table. The OMCL document also provides reference tables that discusses the source of the method (i.e., Ph. Eur. method, validated method form a manufacturer, etc.) and the validation parameters needed to ensure it is an appropriate method for its intended use.
In summary, when performing analytical method validation, validation parameters and elements are determined based on the analytical test method and the intended analytical application.
Vol. 47, No. 2
About RCA Pharmaceutical Services
Regulatory Compliance Associates (RCA)® has helped thousands of pharmaceutical companies meet regulatory, compliance, quality assurance, and remediation challenges. With more than 20 years of experience with FDA, Health Canada, EU and global regulatory agencies worldwide, RCA offers leading pharmaceutical consultants that can help you navigate through the challenges associated with evolving industry regulations.
Our team of over 500 seasoned FDA, Health Canada and EU compliance consultants and regulatory affairs experts can understand the complexities surrounding the pharmaceutical industry and the unique inner workings of the regulatory process.
Whether you’re in the product planning, development or pharmaceutical lifecycle management stage or need a remediation strategy for a compliance crisis, RCA® will guide you through every step of the regulatory process and create a customized approach depending on your product and your pharma company’s individual needs. Our clients include:
- Companies new to FDA, Health Canada or EU regulations and the pharmaceutical industry
- Start-up organizations with novel submissions to 510(k) submissions from multi-national corporations
- Investment firms seeking private equity due diligence for pre-acquisition and post-deal research
- Law firms seeking expertise in the remediation of warning letters, consent decrees, 483’s or import bans
Regulatory affairs is Regulatory Compliance Associates’s® backbone and we fully understand the complexities of the pharmaceutical and biopharmaceutical industries. Our expertise spans all facets and levels of Regulatory Affairs, from Regulatory Support for New Products to Life Cycle Management, to other services like Outsourced Regulatory Affairs, Submissions, Training, and more.
As your partner, we can negotiate the potential assessment minefield of pharmaceuticals with insight, hindsight, and the clear advantage of our breadth and depth of knowledge and experience. We offer the following four regulatory affairs services for pharmaceutical companies.
- New Product Support
- Product Lifecycle
- Other Regulatory Services
The regulations process surrounding pharmaceutical companies can be tricky for even the most experienced industry veteran to understand, and just one misstep could mean significant and lasting consequences for your business. At RCA®, we offer the experience and resources necessary to guide you in quality compliance.
- Method Validation
- Regulatory Agency Response
- Preparation and Training
- Inspection Readiness
Regulatory Compliance Associates’s® Quality Assurance services include assessments, strategy, implementations, staff augmentations, and identification of quality metrics to ensure continuous improvement, aligning with your business needs and goals. Our consultants are quality experts with experience spanning major corporations and start-ups. We know firsthand how to achieve, maintain, and improve quality, and we excel in transferring this knowledge to your organization.
- 21 CFR Part 11
- Data Integrity
- Manufacturing Support
- Facility Support
Regulatory Compliance Associates® Inc. has significant experience and a proven approach to managing FDA Warning Letters, Consent Decrees, Remediation and other serious regulatory situations. We know how to partner with executive, legal, and communication teams, and will assist management with a response that will be accepted by the regulatory agency and be realistic to execute.
We can develop a comprehensive proof book of documented objective evidence demonstrating the corrective actions taken to remediate non-compliant issues. In addition, RCA can help prepare a comprehensive strategy to assist in your remediation efforts, drive continuous improvement, and maintain compliance with the regulations.
- Regulatory Action
- Warning Letter
- 483 Observation
- Oversight Services
Regulatory Compliance Associates® (RCA) provides healthcare consulting services to the following industries for resolution of compliance and regulatory challenges:
We understand the complexities of running a life science business and possess areas of expertise that include every facet of R&D, operations, method validation, regulatory affairs, quality, and manufacturing. We are used to working on the front lines and thriving in the scrutiny of FDA, Health Canada, MHRA and globally-regulated companies.
As your partners, we can negotiate the potential minefield of regulatory compliance and regulatory due diligence with insight, hindsight, and the clear advantage of our unique expertise and experience.
- Founded in 2000
- Headquartered in Wisconsin (USA)
- Expertise backed by over 500 industry subject matter experts
- Acquired by Sotera Health in 2021
About Sotera Health
The name Sotera Health was inspired by Soteria, the Greek goddess of safety, and reflects the Company’s unwavering commitment to its mission, Safeguarding Global Health®.
Sotera Health Company, along with its three best-in-class businesses – Sterigenics®, Nordion® and Nelson Labs®, is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. With a combined tenure across our businesses of nearly 200 years and our industry-recognized scientific and technological expertise, we help to ensure the safety of over 190 million patients and healthcare practitioners around the world every year.
We are a trusted partner to more than 5,800 customers in over 50 countries, including 40 of the top 50 medical device companies and 8 of the top 10 pharmaceutical companies.
To begin the RCA® scoping process today, please enter your information in the blue form below and click the submit button at the bottom of the webpage.